

Evaluation of Serum and Ascitic Fluid Proteomes in Dogs with Dilated Cardiomyopathy ^[1]

Meriç KOCATÜRK ¹  Ahmet Tarık BAYKAL ² Şeyma TÜRKSEVEN ²
Çiğdem ACIOĞLU ² Carlos Fernando AGUDELO ³ Zeki YILMAZ ¹

^[1] This study was partly supported by The Scientific and Technological Research Council of Turkey (TOVAG-1110026)

¹ Uludag University, Veterinary Teaching Hospital, Internal Medicine Department, TR16059Gorukle, Bursa - TURKEY

² TUBITAK Marmara Research Center, Genetic Engineering and Biotechnology Institute, TR-41400 Kocaeli - TURKEY

³ Small Animal Cardiology, Clinic for Diseases of Dogs and Cats, Faculty of Veterinary Medicine, University of Veterinary and Pharmaceutical Sciences, Brno, Palackého tř. 1/3, 612 42 Brno, CZECH REPUBLIC

Article Code: KVFD-2015-14429 Received: 23.09.2015 Accepted: 06.11.2015 Published Online: 13.11.2015

Abstract

The aim of the study was to investigate serum global proteomes in dogs with overt dilated cardiomyopathy (DCM) and to evaluate protein expression in serum with that in ascitic fluid. Eight healthy dogs (control group) and 8 dogs with DCM were included in the study. DCM was diagnosed based on echocardiographic evidence including increased left ventricular dimension at diastole and systole, increased E point to septal separation, and decreased fractional shortening. Serum and ascitic fluid samples were analyzed for proteomes using a label-free LC-MS/MS method. Proteome analyses revealed significantly different expressions of eight proteins in all samples. Expressions in serum of apolipoprotein (Apo) A1, Ig heavy chain V, superoxide dismutase and plasminogen were higher ($P<0.001$), while expressions of clusterin, hemoglobin subunit β , Apo-CII, and $\beta 2$ glycoprotein I ($\beta 2$ GPI) were lower ($P<0.001$) in dogs with DCM than in control dogs. In addition, Apo-A1, clusterin, hemoglobin subunit β , Ig heavy chain V, plasminogen and $\beta 2$ GPI were down-regulated whereas Apo-CII and superoxide dismutase were up-regulated in ascitic fluid compared with serum in dogs with DCM. Data obtained in the present study suggest that serum and/or ascitic fluid proteomes may explain some of the pathophysiological mechanisms involved in the progression of DCM.

Keywords: Dilated cardiomyopathy, DCM, Congestive heart failure, Proteomics, Dog

Dilate Kardiyomiopati Köpeklerde Serum ve Asites Sıvısı Proteomlarının Araştırılması

Özet

Çalışmamızın amacı ileri düzeyde dilate kardiyomiopati (DCM) tanısı konulan köpeklerde serum global proteomların araştırılması ve aynı hastaların asites sıvısı proteomları ile ilişkilerinin değerlendirilmesidir. Sekiz sağlıklı (kontrol grubu) ve 8 DCM'li köpek çalışmaya dahil edildi. DCM tanımlaması ekokardiografik olarak sistol ve diyastolde artmış sol ventriküler çap, artmış E point to septal separasyon değeri ve azalmış fraksiyonel kasılma verileri temelinde yapıldı. Serum ve asites sıvı örnekleri label-free LC-MS/MS metoduna göre analiz edilmiştir. Proteom analizi ile tüm örneklerde toplam sekiz adet proteom ekspresyonu belirlendi. DCM'li köpeklerde kontrol grubuna göre serum apolipoprotein (Apo) A1, Ig heavy chain V, superoksit dizmutaz ve plazminojen ekspresyonlarında artış ($P<0.001$), klasterin, hemoglobin subunit β , Apo-CII, ve $\beta 2$ glikoprotein I ($\beta 2$ GPI) ekspresyonlarında ise azalma ($p<0.001$) belirlendi. Buna ek olarak; asites sıvısı serum örnekleri ile karşılaştırıldığında Apo-A1, klasterin, hemoglobin subunit β , Ig heavy chain V, plazminojen ve $\beta 2$ GPI azalırken, Apo-CII ve superoksit dizmutaz artış gösterdi. Çalışmada elde edilen bu verilerin; serum ve/veya asites sıvısı proteomlarının DCM gelişiminde rolü alan bazı patofizyolojik mekanizmaların açıklanmasına katkı verebileceği kanısındayız.

Anahtar sözcükler: Dilate kardiyomiopati, DCM, Konjestif kalp yetmezliği, Proteomik, Köpek

INTRODUCTION

Dilated cardiomyopathy (DCM) is one of the most common organic heart defects in dogs ^[1]. Echocardiographic features include ventricular dilation, atrial dilation, normal

or thin wall and septal thickness, depressed systolic thickening of the free wall and septum, poor fractional shortening (FS), large E point to septal separation (EPSS), reduced aortic wall motion and global hypokinesis ^[1,2]. Ventricular dilation including generally the left side of the



İletişim (Correspondence)



+90 224 2940817



merick@uludag.edu.tr

heart and poor myocardial function are the main findings of DCM [2]. Such abnormalities of the heart muscle result in chemical and organic reactions cause biomarker release such as natriuretic peptides and cardiac troponins [3]. Many researchers have focused on specific biomarker indicating myocardial injury in DCM [3]; however, new trend of the science is interested in such small peptides, rather than the whole proteins, called proteomics [6].

Proteomics is the large-scale study of protein expression, protein-protein interactions, or post-translational modifications [6-8]. Use of proteomics technology in veterinary medicine is presently under development. Samples and study designs are discussed due to the limitations of mass spectrometry [9]. In veterinary medicine proteomics were performed in such conditions as canine lymphoma [10] and heartworm disease [11] while canine DCM has not yet been studied using proteomics. In addition, although proteomics were performed in several canine body fluids such as cerebrospinal fluid [12], urine [13], bronchoalveolar lavage fluid [14] and follicular fluid [15], no data have yet been presented on ascitic fluid in dogs with DCM. In the present study, we hypothesized that many of the serum proteomes with low abundance and low molecular weight may have roles in the development of DCM in dogs. Besides, proteomic analyses of ascitic fluid may provide further details to explain some pathophysiological mechanism and/or some clinical complications such as abdominal distention and pleural effusion in dogs with DCM.

Therefore, we aimed to analyze expressional proteomics in both serum and ascitic fluid samples, using label-free LC-MS/MS method, in order to present novel data that may help improve our understanding of the pathophysiology of canine DCM.

MATERIAL and METHODS

Animals

Eight dogs with DCM (5 females, 3 males) with different breed (Mixed breed n=4, Terrier n=2, Pointer n=1, Anatolian Sheepdog n=1) and an average age of 54.8 ± 30.8 months (range: 10-96 months), and 8 clinically healthy dogs (4 females, 4 males) with different breed (Mixed breed n=5, Terrier n=2, Anatolian sheepdog n=1) and an average age of 50.2 ± 16.4 months (range: 2 to 8 years) were included in the study. All dogs with DCM were suffering from congestive heart failure (CHF) findings such as cough, lethargy, anorexia, dyspnea, exercise intolerance, abdominal distension and/or pleural effusion.

Electrocardiographic and Echocardiographic Evaluations

After routine clinical examination, electrocardiography (ECG, Esaote, P200® - Florence, Italy), thoracic radiography

and echocardiographic examinations were performed. Two-dimensional (2D) echocardiography, M-mode, color flow imaging and spectral Doppler examinations were performed using a CarisPlus® (Esaote, Florence, Italy) with a 2.5-5 MHz phased-array transducer using standard techniques [2]. The dogs were not sedated throughout the ultrasound examination, and were gently restrained in right lateral recumbency. DCM was diagnosed based on the echocardiographic findings such as increased chamber size, increased EPSS and poor FS along with ECG and thoracic radiographic findings. Diagnosis was confirmed using a scoring system for DCM proposed by European Society for Veterinary Cardiology [2]. Patients presented with all of the criteria for DCM but did not have any other cardiac pathology including congenital malformations or tumors. Dogs with primary congenital heart disease, mitral valve disease or endocrine disorders such as hypothyroidism were excluded.

Radiologic Evaluation

Assessment of cardiomegaly on thoracic radiography was based on a combination of subjective experience and the use of the vertebral heart scale system [16].

Sample Collection and LC-MS/MS Analysis

Serum and ascitic fluid samples were obtained from patients before the treatment. Samples were kept in -80°C freezer until being sent in cold chain to the laboratory for analyses [TUBITAK, Genetical Engineering and Biotechnology Institute (GEBI), Gebze, Kocaeli, Turkey].

Protein expression analyses in serum and ascetic fluid samples were performed using a label-free nano liquid chromatography - mass spectrometry method. Extracted proteins from the samples were reduced with dithiothreitol (DTT; 5 mM, 15 min) and alkylated with iodoacetic acid (IAA; 10 mM, 30 min at dark). Tryptic peptides were generated by incubating the protein mixture at 37°C with sequencing grade trypsin (1:50 ratio, Pierce). The peptide mixture was loaded on a nanoACQUITY UPLC Symmetry C18 Trap column (5 µm particle size, 180 µm i.d. x 20 mm length) at 5 µl/min flow rate for 5 min. Peptides were eluted from the trap column by gradient elution onto an analytical column (nanoACQUITY UPLC BEH C18 Column, 1.7 µm particle size, 75 µm i.d. x 250 mm length, Waters), at 300 nl/min flow rate with a linear gradient from 5 to 40% acetonitrile over 90 min. Data independent acquisition mode (MS^E) was carried out by operating the instrument at positive ion V mode. Mass drift was corrected by the internal mass calibrant glu-fibrinopeptide infused every 45 sec through the nanolockspray ion source at 300 nl/min flow rate. Peptide signal data between 50-1.600 m/z values were collected. Data processing parameters were set to standard operating values [17]. The Apex3D parameters were set to 0.2 min chromatographic peak width and 10.000 TOF resolution. 150, 50 and 1.200 counts were set

for low energy, elevated energy and intensity threshold, respectively. Tandem mass spectra extraction, charge state deconvolution and deisotoping were processed with ProteinLynx Global Server v2.3 software (PLGS) (Waters Corp., Milford, MA). Protein sequence database from Uniprot was used. Databank search query was set to minimum 3 fragment ion matches per peptide, minimum 7 fragment ion matches per protein, minimum 1 peptide matches per protein and 1 missed cleavage. Carbamidomethyl-cysteine fixed modification and Acetyl N-terminal, deamidation of asparagine and glutamine, oxidation of methionine variable modifications were set. Normalization of the proteins was achieved against the digest of the internal calibrant P00330.

Statistical Analyses

Data were analyzed by Student's t test using SPSS 10.0 Statistical Software (SPSS Inc), and the results were expressed as Mean \pm Standard error of means (SEM). The intensity % coefficient of variation (%CV Int) were calculated to be around 14% across the identified proteins so three times the %CV Int value is set for the cut-off for statistical significance. Only proteins expressional changes showing more than 40% up-regulation or down-regulation were reported. For all comparisons, values of $P < 0.05$ were considered significant.

RESULTS

Clinical Findings

Clinical charts of dogs with DCM included dyspnea (6/8), lethargy (4/8), exercise intolerance (8/8), and anorexia (5/8). Clinical examination revealed weak femoral artery pulse, distension of the jugular vein, abdominal distension, increased cardiac auscultation area and mitral and/or tricuspid murmurs with different severities in all patients with DCM.

Electrocardiographic (ECG) Findings

ECG analysis revealed some cardiac rhythms abnormalities in dogs with DCM in which atrial fibrillation (5/8) (Fig. 1), ventricular extra systoles (2/8), atrioventricular block (1/8) and sinus tachycardia (2/8) were the most common.

Radiological Findings

Enlarged heart size, deviation of the trachea, mild to severe pulmonary edema, increased vertebral heart scale (14.2 ± 1.3), pulmonary pattern, caudal vena cava distension, and pleural and peritoneal effusions were observed on thoracic radiography in dogs with DCM (Fig. 2).

Two-dimensional Echocardiographic Findings

All dogs with DCM had geometric and functional cardiac abnormalities. LA diameter (4.62 ± 0.4 cm), LA/Ao ratio (2.08 ± 0.4), left ventricular diastole diameter (6.3 ± 0.7 cm) and EPSS value (1.1 ± 0.3 cm) were above the reference limits. Poor FS ($15.8 \pm 4.8\%$) was observed in dogs with DCM, as well (Table 1, Fig. 3). Pulmonary artery flow velocity was higher ($P < 0.001$) but aortic flow velocity was lower ($P < 0.001$) than those of healthy controls (Table 1).

Serum and Ascitic Fluids Proteomics

Expressions of 8 proteins (Apolipoprotein[Apo]A1, hemoglobin subunit β , clusterin, Ig heavy chain V region, Apo-CII, plasminogen, b 2 glycoprotein I [$\beta 2$ GPI] and superoxide dismutase) differed significantly in blood and ascitic fluid samples (Table 2). Apo-A1, Ig heavy chain V, superoxide dismutase and plasminogen expressions in serum samples were higher ($P < 0.05 - 0.01$), while clusterin, hemoglobin subunit β , Apo-CII and $\beta 2$ GPI expressions were lower ($P < 0.05 - 0.001$) in dogs with DCM than in healthy controls. Expressions of Apo-A1, clusterin, hemoglobin subunit β , Ig heavy chain V, plasminogen, and $\beta 2$ GPI were




Fig 1. ECG from a dog with DCM (7 year-old, male, Turkish Shepherd Dog) revealed an atrial fibrillation due to absence of "P waves" and increased heart frequency (Calibration: 50 mm/second, 10 mm/1 mV)

Şekil 1. DCM'li bir köpek EKG'sinde (7 yaşlı, erkek, Kangal) 'P dalgalarının' olmaması ve artmış kalp frekansı nedeniyle atriyal fibrilasyon belirlenmiştir (Kalibrasyon: 50 mm/saniye, 10 mm/1 mV)




Fig 2. Radiologic evaluation of the thorax in a 8-year-old male Turkish Shepherd Dog. A: The right lateral radiograph points out the general lung tissue opacity, dorsal deviation of the trachea and the vascular hilus, bronchiectasis of the cranial lobe bronchus and enlargement of the heart borders in the thoracic cavity, B: The ventrodorsal radiograph shows general opacity, alveolar model influence of the lung lobes and unclear hearth silhouette as well as left side shift of the hearth suspected due to cardiomegaly

Şekil 2. 8 yaşlı erkek Kangal bir köpekte toraksın radyolojik olarak değerlendirilmesi. A: Sağ lateral radyografi genel akciğer dokusu opasitesindeki artışı, trakeanın dorsale deviyasyonu ve hilus vaskülarizasyonunu, kranial lob bronşunda bronşiyektazi ve torasik boşlukta kalbin sınırlarının genişlemiş olduğunu vurgulamaktadır, B: Ventrodorsal grafi genel opasite, akciğer loblarında alveoler etkilenim ve şüphelenilen kardiyomyopati nedeniyle sol tarafa kaymaya ek olarak belirsiz kalp silüyeti belirtmektedir




Fig 3. M-mode measurement of the left ventricle at right parasternal short axis view showed increased chamber size, poor fractional shortening and interventricular septal akinesia. Hyperechoic line in the pericardial sac indicated mild pericardial effusion (A). Left atrial dilation (left atrium/aorta ratio: 1.7) was observed on right parasternal short axis view - aortic level (B)

Şekil 3. Sol ventrikülün sağ parasternal kısa eksen M-mod görüntüsü artmış odacık büyüklüğü, zayıf fraksiyonel kısalma ve interventriküler septal akinezi olduğunu göstermiştir. Perikardiyal kesedeki hiperekoik çizgi hafif bir parikardiyal efüzyonu işaret etmektedir (A). Sağ parasternal kısa eksen görüntü- ortik düzeyde sol atriyal genişleme (Sol atriyum /aorta oranı: 1.7) belirlenmiştir (B)

down-regulated whereas expressions of Apo-CII and superoxide dismutase were up-regulated in ascitic fluid compared with serum in dogs with DCM.

DISCUSSION

The present study reported, for the first time, evaluation of protein expression changes in blood and

ascitic fluid of dogs with DCM and made comparisons with regard to serum proteomes between dogs with DCM and healthy controls. Significant differences were detected in expressions of a total of 8 proteins (Apo-A1, hemoglobin subunit β , clusterin, Ig heavy chain V region, Apo-CII, plasminogen, β 2GPI and superoxide dismutase) in both serum and ascitic fluid of dogs with DCM. In the study, DCM was diagnosed based on the echocardiographic

Tablo 1. DCM'li ve sağlıklı köpeklerin ekokardiografik parametreleri (Mean ± SE)**Table 1.** Echocardiographic parameters of the dogs with DCM and healthy dogs (Mean ± SE)

Parameter	Dogs with DCM n=8	Healthy dogs n=8	P value
Body weight (Kg)	32.2 ±8.5	28.4±4.3	ns
IVSD (cm)	1.1±0.5	0.82±0.06	<0.01
IVSs (cm)	2.53±1.17	1.63±0.41	ns
LVDd (cm)	6.37 ±0.7	4.54±0.33	<0.001
LVDs (cm)	5.4±0.7	3.20±0.25	<0.001
PWd (cm)	0.88±0.37	0.94±0.11	<0.01
PWs (cm)	1.03±0.34	1.05±0.12	ns
Ao diameter (cm)	2.22 ±0.4	2.0±0.1	ns
LA diameter (cm)	4.62±0.4	2.3±0.0	<0.001
LA/Ao ratio	2.08±0.4	1.2±0.0	<0.001
EPSS (cm)	1.1±0.3	0.3±0.1	<0.001
FS %	15.8±4.8	30.20±2.41	<0.001
PA Vmax m/s	0.6±0.09	0.33±0.03	<0.001
AoVmax m/s	0.7±0.14	1.3±0.1	<0.001

BW: body weight; **IVSD:** interventricular septum diastole; **IVSs:** interventricular septum systole; **LVDd:** left ventricular diameter diastole; **LVDs:** left ventricular diameter systole; **PWd:** post wall diastole; **PWs:** post wall systole; **Ao:** aorta; **LA:** left atrium; **LA/Ao ratio:** left atrium/aorta ratio; **EPSS:** E-point to septal separation; **FS:** fractional shortening; **PA:** pulmonary artery; **ns:** not significant

Table 2. List of the protein expression results and fold changes (+ increase; - decrease) between serum from dogs with DCM (DCM) and healthy controls (H) or ascitic fluid (A)**Tablo 2.** DCM'li (DCM) ve sağlıklı (H) köpeklerin serumları veya asites sıvıları (A) arasındaki protein salınım sonuçlarının ve son değerlerin başlangıç değerlerine oranlarının listesi (+ artış; - azalış)

Accession #	Description	Fold Change	
		DCM vs H	DCM vs A
P02648	Apolipoprotein A 1	1.42 (+)**	1.41 (+)**
P25473	Clusterin	1.40 (-)*	1.21 (+)*
P60524	Hemoglobin subunit β	1.40 (-)*	3.65 (+)**
P01784	Ig heavy chain V region GOM	1.41 (+)**	1.77 (+)**
P12278	Apolipoprotein C II	354.8 (-)***	299.7 (-)***
P80009	Plasminogen Fragment	1.44 (+)**	1.36 (+)**
P33703	β 2 Glycoprotein 1	2.31 (-)**	47.6 (+)***
O54210	Superoxide dismutase Mn Fe fragment	1.65 (+)*	1.66 (-)*

vs - versus, * P<0.05, ** P<0.01, s*** P<0.001

findings along with ancillary diagnostic tests including ECG and thoracic radiography, as suggested [2].

Clusterin has a protective role on stress-mediated apoptosis, oxidative stress and protein aggregation inhibition [18]. Cardiorenal syndrome may be another

reason for low serum clusterin level, since clusterin is also a renal damage biomarker in dogs [19,20]. Increased vascular permeability due to serum protein escape from the blood stream and the venous return loss in response to heart failure might be responsible of low clusterin levels in dogs with DCM studied. In the present study, the possible reason for decreased level of serum clusterin in dogs with DCM may be related with the result of excessive use of the protein in situations such as increased cell death and oxidative stress status.

Previous studies suggested that Apo-A1 is responsible of cholesterol transport from tissues to the liver [11]. However *vena cava caudalis* pressure overload as a result of decreased venous return to the heart may play a role on liver-ischemia-induced loss of free cholesterol esterification. In this pathophysiology, high blood cholesterol plays a role on erythrolysis and hemoglobin release [11]. The mild increase in hemoglobin subunit β protein detected in the present study might have resulted from increased demand of O₂ in the body in response to decreased cardiac output (lower aortic flow velocity), the myocardial contractility loss (lower FS), and decreased venous return (Jugular distention and higher pulmonary artery flow velocity) in dogs with DCM. An increased O₂ demand may be explained by superoxide anion radical formation in conjunction with increased superoxide dismutase, an antioxidant protein. β₂GPI molecule was classified as an Apo, and it was initially termed Apo-H [21]. Among connected results, decreased level of serum Apo-H might be a result of protection mechanism against oxidative stress induced by apoptotic ischemic cells. Consistent with this hypothesis, Apo-H was shown to be present in atherosclerotic plaques [22] and involved in apoptosis process at surfaces of cells undergoing apoptosis [21,23].

In our study, Apo-CII was low (354.8 fold change) in serum samples of dogs with DCM. This might be the result of increased permeability of veins and impaired circulation ended with Apo-CII escape from circulation to ascites fluid. Apo-CII was reported to be a cofactor for lipoprotein lipase and identified as a putative substrate of matrix metalloproteinases (MMP-7, MMP-14) in humans, and a deficiency in Apo-CII was associated with atherosclerosis [24]. In good accordance, Kawano *et al.* [25] showed that a mutation in the Apo-II gene caused coronary atherosclerosis. Since canine Apo-CII has not been studied yet, we can only speculate that it might be involved in pathogenesis of atherosclerosis as in humans.

Venous return loss, impaired circulation and pleural and peritoneal effusion, as observed in the present study, are the signs of congestive heart failure (CHF) in dogs with DCM [1,2]. A previous study [26] reported high plasma fibrinogen, D-dimer, thrombin-antithrombin complex and low anti-thrombin activity in dogs with chronic CHF. We showed, in the present study, changes in expressions of

proteins related with coagulation in dogs with DCM, based on serum proteomics data including increased expression of plasminogen and decreased expression of β_2 GPI. It is well known that plasminogen has a fibrinolytic activity, and β_2 GPI has procoagulant and anticoagulant activities in the coagulation cascade [27]. β_2 GPI can also bind to plasminogen and lipoprotein A, a molecule conferring a putative risk for atherosclerotic disease in humans [21]. It may thus be suggested that plasminogen and β_2 GPI act together to regulate intrinsic fibrinolytic pathways in dogs with DCM [21,27].

On the other hand, our study has several limitations. The number of the dogs is not enough to represent the whole population, because this is a pilot study in which specific breed or sex variation was not investigated. In addition, while our results seem like not related with breed type or sex, physiological states like ovulation may be involved in alterations in serum proteomics. These limitations warrant a larger-scale study.

Since hematological or endocrinological changes would change the proteomic scale, serum proteome mapping of the dogs with DCM was challenging. Despite having controlled many variables, still some other mechanisms might have affected the analysis results. Serum proteomics can easily be affected by physiological conditions therefore proteins found in this study might be altered by physiological variables [9]. In parallel with this explanation, human studies showed that patients show different proteomic patterns in pathophysiological conditions such as sepsis [28] and diabetes mellitus [29].

There are some studies on structural proteomics of the canine heart [30,31], and our study did not include brain natriuretic peptide or cardiac troponin I detection in both samples (serum and ascitic fluid). This might be associated with potential loss of high molecular bounded target proteins in protein immune-affinity depletion step of the proteomic analysis technique or binding to the depletion column [32-34]. Immune-affinity depletion is essential for eliminating most abundant proteins such as albumin, but loss of target proteins in this step narrows the data and makes more questionable [9].

In conclusion, the study presented here that DCM in dogs shows different peptide pattern in the blood stream, which are the result of increased O₂ demand, hemostatic and fibrinolytic system changes and oxygen free radicals and progressive organ damage, as well as the heart itself. In this study, observed proteomes in serum and ascitic fluid samples enhances the search for informative biomarkers in biological samples from healthy dogs or dogs with DCM, thus allowing an earlier and more precise diagnosis and a deeper comprehension of pathogenesis, development and outcome of cardiomyopathy. Proteomic analysis in dogs with DCM may be useful to evaluate dynamic pathophysiological changes of the disease process, and

especially serum Apo-CII level may be accepted as a risk factor for developing DCM in dogs.

ACKNOWLEDGEMENTS

We thank Prof. Dr. Mehmet CANSEV (Dep. of Pharmacology, Medical Faculty, Uludag University, Bursa, Turkey) for his comments and grammatical correction of the manuscript.

CONFLICT OF INTEREST

None of the authors of this article has a financial or personal relationship with other people or organizations that could inappropriately influence or bias the content of the paper.

REFERENCES

- Martin MW, Stafford Johnson MJ, Strehlau G, King JN:** Canine dilated cardiomyopathy: A retrospective study of prognostic findings in 367 clinical cases. *J Small Anim Pract*, 8, 428-436, 2010. DOI: 10.1111/j.1748-5827.2010.00966.x
- Boon JA:** Veterinary Echocardiography, 2nd ed., Wiley-Blackwell, USA, 2010.
- Oyama MA:** Using cardiac biomarkers in veterinary practice. *Vet Clin North Am: Small Anim Pract*, 43, 1261-1272, 2013. DOI: 10.1016/j.cvs.2013.07.010
- Çakıroğlu D, Meral Y, Bakirel U, Kazancı D:** Cardiac Troponin Levels in Dogs with Dilate Cardiomyopathy. *Kafkas Univ Vet Fak Derg*, 15, 13-17, 2009. DOI: 10.9775/kvfd.2008.31-A
- Güneş V, Uyanık F, Eren M, Kibar M, Aslan Ö, Onmaz AC:** The rapid analyses of cardiac troponins in dogs with dilated cardiomyopathy, distemper or parvovirus infection. *Kafkas Univ Vet Fak Derg*, 20, 921-927, 2014. DOI: 10.9775/kvfd.2014.11403
- Basaran E, Aras S, Cansaran-Duman D:** Genomik, proteomik, metabolomik kavramlarına genel bakış ve uygulama alanları. *Türk Hijyen ve Deneysel Biyoloji Dergisi*, 67 (2): 85-96, 2010.
- Bantscheff M, Schirle, M, Sweetman G, Rick J, Kuster B:** Quantitative mass spectrometry in proteomics: A critical review. *Anal Bioanal Chem*, 389, 1017-1031, 2007.
- Kurban S, Mehmetoğlu İ:** Proteomik. *Yeni Tıp Dergisi*, 27, 70-75, 2010.
- Lippolis JD, Reinhardt TA:** Utility, limitations, and promise of proteomics in animal science. *Vet Immunol Immunopathol*, 138, 241-251, 2010. DOI: 10.1016/j.vetimm.2010.10.003
- Atherton MJ, Braceland M, Fontaine S, Waterston MM, Burchmore RJ, Eadie S, Eckersall PD, Morris JS:** Changes in the serum proteome of canine lymphoma identified by electrophoresis and mass spectrometry. *Vet J*, 196, 320-324, 2013. DOI: 10.1016/j.tvjl.2012.12.010
- Hormaeche ME, Carretón E, González-Miguel J, Gussoni S, Montoya-Alonso JA, Simón F, Morchón R:** Proteomic analysis of the urine of *Dirofilaria immitis* infected dogs. *Vet Parasitol*, 203, 241-246, 2014. DOI: 10.1016/j.vetpar.2014.01.025
- Martin-Vaquero P, da Costa RC, Allen MJ, Moore SA, Keirse JK, Green KB:** Proteomic analysis of cerebrospinal fluid in canine cervical spondylomyelopathy. *Spine*, 40, 601-612, 2015. DOI: 10.1097/BRS.0000000000000831
- Brandt LE, Ehrhart EJ, Scherman H, Olver CS, Bohn AA, Prenni JE:** Characterization of the canine urinary proteome. *Vet Clin Pathol*, 43, 193-205, 2014. DOI: 10.1111/vcp.12147
- Lenz AG, Meyer B, Weber H, Maier K:** Two-dimensional electrophoresis of dog bronchoalveolar lavage fluid proteins. *Electrophoresis*, 11, 510-513, 1990. DOI: 10.1002/elps.1150110616

- 15. Fahiminiya S, Reynaud K, Labas V, Batard S, Chastant-Maillard S, Gérard N:** Steroid hormones content and proteomic analysis of canine follicular fluid during the preovulatory period. *Reprod Biol Endocrinol*, 8, 132, 2008. DOI: 10.1186/1477-7827-8-132
- 16. Buchanan JW, Bücheler J:** Vertebral scale system to measure canine heart size in radiographs. *J Am Vet Med Assoc*, 206 (2): 194-199, 1995.
- 17. Hacariz O, Sayers G, Baykal AT:** A proteomic approach to investigate the distribution and abundance of surface and internal *Fasciola hepatica* proteins during the chronic stage of natural liver fluke infection in cattle. *J Proteome Res*, 11, 3592-3604, 2012. DOI: 10.1021/pr300015p
- 18. Trougakos IP, So A, Jansen B, Gleave ME, Gonos ES:** Silencing expression of the Clusterin/apolipoprotein J gene in human cancer cells using small interfering RNA induces spontaneous apoptosis, reduced growth ability, and cell sensitization to genotoxic and oxidative stress. *Cancer Res*, 64, 1834, 2004.
- 19. García-Martínez JD, Tvarijonavičiute A, Cerón JJ, Caldin M, Martínez-Subiela S:** Urinary clusterin as a renal marker in dogs. *J Vet Diagn Invest*, 24, 301, 2012. DOI: 10.1177/1040638711435112
- 20. Zhou X, Ma B, Lin Z, Qu Z, Huo Y, Wang J, Li B:** Evaluation of the usefulness of novel biomarkers for drug-induced acute kidney injury in beagle dogs. *Toxicol App Pharmacol*, 280, 30-35, 2014. DOI: 10.1016/j.taap.2014.07.002
- 21. Miyakis S, Giannakopoulos B, Krilis SA:** Beta 2 glycoprotein I-function in health and disease. *Thromb Res*, 114, 335-346, 2004. DOI: 10.1016/j.thromres.2004.07.017
- 22. George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman J, Barshack I, Kopolovic J, Shoenfeld Y:** Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. *Circulation*, 99 (17): 2227-2230, 1999. DOI: 10.1161/01.CIR.99.17.2227
- 23. Wang WL, Meng ZX, Zhou SJ, Li CJ, Chen R, Lv L, Ma ZJ, Yu DM, Yu P:** Reduced beta2-glycoprotein I protects macrophages from ox-LDL-induced foam cell formation and cell apoptosis. *Lipids Health Dis*, 12, 174, 2013. DOI: 10.1186/1476-511X-12-174
- 24. Kim SY, Park SM, Lee ST:** Apolipoprotein C-II is a novel substrate for matrix metalloproteinases. *Biochem Biophys Res Commun*, 339 (1): 47-54, 2006. DOI: 10.1016/j.bbrc.2005.10.182
- 25. Kawano M, Kodama K, Inadera H, Saito Y, Saito M, Yaginuma T, Kanazawa Y, Kawakami M:** A case of apolipoprotein C-II deficiency with coronary artery disease. *Clin Exp Med*, 2 (1): 29-31, 2002.
- 26. Tarnow I, Falk T, Tidholm A, Martinussen T, Jensen AL, Olsen LH, Pedersen HD, Kristensen AT:** Hemostatic biomarkers in dogs with chronic congestive heart failure. *J Vet Intern Med*, 21, 451-457, 2007.
- 27. Bu C, Gao L, Xie W, Zhang J, He Y, Cai G, McCrae KR:** Beta2-glycoprotein 1 is a cofactor for tissue plasminogen activator-mediated plasminogen activation. *Arthritis Rheum*, 60, 559-568, 2009. DOI: 10.1002/art.24262
- 28. Kalenka A, Feldmann RE, Jr Otero K, Maurer MH, Waschke KF, Fiedler F:** Changes in the serum proteome of patients with sepsis and septic shock. *Anesth Analg*, 103, 1522-1526, 2006. DOI: 10.1213/01.ane.0000242533.59457.70
- 29. Zhi W, Sharma A, Purohit S, Miller E, Bode B, Anderson SW, Reed JC, Steed RD, Steed L, Hopkins D, She JX:** Discovery and validation of serum protein changes in type 1 diabetes patients using high throughput two dimensional liquid chromatography-mass spectrometry and immunoassays. *Mol Cell Proteomics*, 10, 2011. DOI: 10.1074/mcp.M111.012203
- 30. Kirk JA, Holewinski RJ, Kooij V, Agnetti G, Tunin RS, Witayavanitkul N, de Tombe PP, Gao WD, Van Eyk J, Kass DA:** Cardiac resynchronization sensitizes the sarcomere to calcium by reactivating GSK-3 β . *J Clin Invest*, 124 (1): 129-138, 2014. DOI: 10.1172/JCI69253
- 31. Seilhamer JJ, Arfsten A, Miller JA, Lundquist P, Scarborough RM, Lewicki JA, Porter JG:** Human and canine gene homologs of porcine brain natriuretic peptide. *Biochem Biophys Res Commun*, 165, 650-658, 1989. DOI: 10.1016/S0006-291X(89)80015-4
- 32. Keshishian H, Addona T, Burgess M, Kuhn E, Carr SA:** Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. *Mol Cell Proteomics*, 6 (12): 2212-2229, 2007.
- 33. Liu T, Qian, WJ, Mottaz HM, Gritsenko MA, Norbeck AD, Moore RJ, Purvine SO, 2nd Camp DG, Smith RD:** Evaluation of multi protein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry. *Mol Cell Proteomics*, 5 (11): 2167-2174, 2006. DOI: 10.1074/mcp.T600039-MCP200
- 34. Liu T, Hossain M, Schepmoes AA, Fillmore TL, Sokoll LJ, Kronewitter SR, Izmirlian G, Shi T, Qian WJ, Leach RJ, Thompson IM, Chan DW, Smith RD, Kagan J, Srivastava S, Rodland KD, 2nd Camp DG:** Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: Correlation with clinical immunoassay tests. *J Proteomics*, 75, 4747-4757, 2012. DOI: 10.1016/j.jprot.2012.01.035